Pfizer Invites Public to Register for Webcast of Analyst and Investor Call to Review Oncology Business on April 9, 2021 Pharmaceutical Investing
BLU SHAREHOLDER FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff in a Securities Class Action Lawsuit Against BELLUS Health, Inc. Biotech Investing
BLU Investor Notice: Rosen, A Respected and Leading Firm, Encourages BELLUS Health Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - BLU Biotech Investing
Genix Pharmaceuticals Corporation Enters into Exclusive License and Supply Agreement for Canada’s First Generic Thyroid Medication Life Science Investing
Kite Submits Supplemental Biologics License Application to U.S. Food and Drug Administration for Tecartus® in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Biotech Investing
Cardiol Therapeutics Announces Filing of 2020 Year-End Financial Statements and MD&A Biotech Investing
New England Journal of Medicine Publishes 24-Week Results from Phase 3 Study Evaluating RINVOQ in Psoriatic Arthritis Biotech Investing
Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study Pharmaceutical Investing
Abbott's BinaxNOW Rapid Antigen Self Test Receives FDA Emergency Use Authorization for Asymptomatic, Over-the-Counter, Non-Prescription, Multi-Test Use Medical Device Investing
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages BELLUS Health Inc. Investors with Large Losses to Secure Counsel Before Important Deadline in Securities Class Action - BLU Biotech Investing
